PURPOSE: To improve the significance of insulin-like growth factor-binding protein 5 (IGFBP-5) as a prognostic and potentially predictive marker in patients with breast cancer. EXPERIMENTAL DESIGN: Increased IGFBP-5 expression was identified in MCF-7 cells resistant (MCF-7R4) to the IGF-1R/insulin receptor (InsR) inhibitor BMS-536924 and its role examined by targeted knockdown and overexpression in multiple experimental models. Protein expression of IGFBP-5 was measured by immunohistochemistry in a cohort of 76 patients with breast cancer to examine correlative associations with invasive tumor fraction and outcome. The use of a combined IGFBP-5/IGFBP-4 (BPR) expression ratio was applied to predict anti-IGF-1R/InsR response in a panel of breast cancer lines and outcome in multiple breast tumor cohorts. RESULTS: IGFBP-5 knockdown decreased BMS-536924 resistance in MCF-7R4 cells, whereas IGFBP-5 overexpression in MCF-7 cells conferred resistance. When compared with pathologically normal reduction mammoplasty tissue, IGFBP-5 expression levels were upregulated in both invasive and histologically normal adjacent breast cancer tissue. In both univariate and multivariate modeling, metastasis-free survival, recurrence free survival (RFS), and overall survival (OS) were significantly associated with high IGFBP-5 expression. Prognostic power of IGFBP-5 was further increased with the addition of IGFBP-4 where tumors were ranked based upon IGFBP-5/IGFBP-4 expression ratio (BPR). Multiple breast cancer cohorts confirm that BPR (high vs. low) was a strong predictor of RFS and OS. CONCLUSION: IGFBP-5 expression is a marker of poor outcome in patients with breast cancer. An IGFBP-5/IGFBP-4 expression ratio may serve as a surrogate biomarker of IGF pathway activation and predict sensitivity to anti-IGF-1R targeting.
PURPOSE: To improve the significance of insulin-like growth factor-binding protein 5 (IGFBP-5) as a prognostic and potentially predictive marker in patients with breast cancer. EXPERIMENTAL DESIGN: Increased IGFBP-5 expression was identified in MCF-7 cells resistant (MCF-7R4) to the IGF-1R/insulin receptor (InsR) inhibitor BMS-536924 and its role examined by targeted knockdown and overexpression in multiple experimental models. Protein expression of IGFBP-5 was measured by immunohistochemistry in a cohort of 76 patients with breast cancer to examine correlative associations with invasive tumor fraction and outcome. The use of a combined IGFBP-5/IGFBP-4 (BPR) expression ratio was applied to predict anti-IGF-1R/InsR response in a panel of breast cancer lines and outcome in multiple breast tumor cohorts. RESULTS:IGFBP-5 knockdown decreased BMS-536924 resistance in MCF-7R4 cells, whereas IGFBP-5 overexpression in MCF-7 cells conferred resistance. When compared with pathologically normal reduction mammoplasty tissue, IGFBP-5 expression levels were upregulated in both invasive and histologically normal adjacent breast cancer tissue. In both univariate and multivariate modeling, metastasis-free survival, recurrence free survival (RFS), and overall survival (OS) were significantly associated with high IGFBP-5 expression. Prognostic power of IGFBP-5 was further increased with the addition of IGFBP-4 where tumors were ranked based upon IGFBP-5/IGFBP-4 expression ratio (BPR). Multiple breast cancer cohorts confirm that BPR (high vs. low) was a strong predictor of RFS and OS. CONCLUSION:IGFBP-5 expression is a marker of poor outcome in patients with breast cancer. An IGFBP-5/IGFBP-4 expression ratio may serve as a surrogate biomarker of IGF pathway activation and predict sensitivity to anti-IGF-1R targeting.
Authors: Bo Young Ahn; Adam N Elwi; Byoungchun Lee; Diane L N Trinh; Alexander C Klimowicz; Annie Yau; Jennifer A Chan; Anthony Magliocco; Sung-Woo Kim Journal: Cancer Res Date: 2010-03-30 Impact factor: 12.701
Authors: Xiaonan Hou; Fei Huang; Joan M Carboni; Karen Flatten; Yan W Asmann; Cynthia Ten Eyck; Takeo Nakanishi; Jennifer D Tibodeau; Douglas D Ross; Marco M Gottardis; Charles Erlichman; Scott H Kaufmann; Paul Haluska Journal: Mol Cancer Ther Date: 2011-01 Impact factor: 6.261
Authors: J Ma; M N Pollak; E Giovannucci; J M Chan; Y Tao; C H Hennekens; M J Stampfer Journal: J Natl Cancer Inst Date: 1999-04-07 Impact factor: 13.506
Authors: Richard Quek; Qian Wang; Jeffrey A Morgan; Geoffrey I Shapiro; James E Butrynski; Nikhil Ramaiya; Tarsha Huftalen; Nicole Jederlinic; Judith Manola; Andrew J Wagner; George D Demetri; Suzanne George Journal: Clin Cancer Res Date: 2010-12-22 Impact factor: 12.531
Authors: B C Turner; B G Haffty; L Narayanan; J Yuan; P A Havre; A A Gumbs; L Kaplan; J L Burgaud; D Carter; R Baserga; P M Glazer Journal: Cancer Res Date: 1997-08-01 Impact factor: 12.701
Authors: Julie A Vendrell; Katherine E Robertson; Patrice Ravel; Susan E Bray; Agathe Bajard; Colin A Purdie; Catherine Nguyen; Sirwan M Hadad; Ivan Bieche; Sylvie Chabaud; Thomas Bachelot; Alastair M Thompson; Pascale A Cohen Journal: Breast Cancer Res Date: 2008-10-17 Impact factor: 6.466
Authors: Nalo Hamilton; Diana Marquez-Garban; Vei H Mah; Yahya Elshimali; David Elashoff; Edward B Garon; Jaydutt Vadgama; Richard Pietras Journal: Crit Rev Oncog Date: 2015
Authors: Asaf Wyszynski; Chi-Chen Hong; Kristin Lam; Kyriaki Michailidou; Christian Lytle; Song Yao; Yali Zhang; Manjeet K Bolla; Qin Wang; Joe Dennis; John L Hopper; Melissa C Southey; Marjanka K Schmidt; Annegien Broeks; Kenneth Muir; Artitaya Lophatananon; Peter A Fasching; Matthias W Beckmann; Julian Peto; Isabel Dos-Santos-Silva; Elinor J Sawyer; Ian Tomlinson; Barbara Burwinkel; Frederik Marme; Pascal Guénel; Thérèse Truong; Stig E Bojesen; Børge G Nordestgaard; Anna González-Neira; Javier Benitez; Susan L Neuhausen; Hermann Brenner; Aida Karina Dieffenbach; Alfons Meindl; Rita K Schmutzler; Hiltrud Brauch; Heli Nevanlinna; Sofia Khan; Keitaro Matsuo; Hidemi Ito; Thilo Dörk; Natalia V Bogdanova; Annika Lindblom; Sara Margolin; Arto Mannermaa; Veli-Matti Kosma; Anna H Wu; David Van Den Berg; Diether Lambrechts; Hans Wildiers; Jenny Chang-Claude; Anja Rudolph; Paolo Radice; Paolo Peterlongo; Fergus J Couch; Janet E Olson; Graham G Giles; Roger L Milne; Christopher A Haiman; Brian E Henderson; Martine Dumont; Soo Hwang Teo; Tien Y Wong; Vessela Kristensen; Wei Zheng; Jirong Long; Robert Winqvist; Katri Pylkäs; Irene L Andrulis; Julia A Knight; Peter Devilee; Caroline Seynaeve; Montserrat García-Closas; Jonine Figueroa; Daniel Klevebring; Kamila Czene; Maartje J Hooning; Ans M W van den Ouweland; Hatef Darabi; Xiao-Ou Shu; Yu-Tang Gao; Angela Cox; William Blot; Lisa B Signorello; Mitul Shah; Daehee Kang; Ji-Yeob Choi; Mikael Hartman; Hui Miao; Ute Hamann; Anna Jakubowska; Jan Lubinski; Suleeporn Sangrajrang; James McKay; Amanda E Toland; Drakoulis Yannoukakos; Chen-Yang Shen; Pei-Ei Wu; Anthony Swerdlow; Nick Orr; Jacques Simard; Paul D P Pharoah; Alison M Dunning; Georgia Chenevix-Trench; Per Hall; Elisa Bandera; Chris Amos; Christine Ambrosone; Douglas F Easton; Michael D Cole Journal: Hum Mol Genet Date: 2016-07-11 Impact factor: 6.150
Authors: Arun Rajan; Corey A Carter; Arlene Berman; Liang Cao; Ronan J Kelly; Anish Thomas; Sean Khozin; Ariel Lopez Chavez; Isabella Bergagnini; Barbara Scepura; Eva Szabo; Min-Jung Lee; Jane B Trepel; Sarah K Browne; Lindsey B Rosen; Yunkai Yu; Seth M Steinberg; Helen X Chen; Gregory J Riely; Giuseppe Giaccone Journal: Lancet Oncol Date: 2014-01-15 Impact factor: 41.316